Overview
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Status:
Completed
Completed
Trial end date:
0000-00-00
0000-00-00
Target enrollment:
93
93
Participant gender:
Both
Both
Summary
The purpose of this study is to determine the dose of the bispecific T cell engager blinatumomab (MT103) in pediatric and adolescent patients with relapsed/refractory Acute Lymphoblastic Leukemia (ALL) and to assess whether this dose of blinatumomab is effective.Phase:
Phase 1/Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Amgen Research (Munich) GmbHTreatments:
Antibodies, Bispecific
BlinatumomabLast Updated:
2016-07-12
Criteria
Inclusion Criteria:- Morphologic evidence of B-precursor ALL with > 25% blasts in bone marrow (M3)at study
enrolment
- Age less than 18 years at enrollment
- Relapsed/refractory disease:
- Second or later bone marrow relapse,
- Any marrow relapse after allogeneic HSCT, or
- Refractory to other treatments: Patients in first relapse must have failed to
achieve a CR following full standard reinduction chemotherapy regimen of at
least 4 weeks duration.Patients who have not achieved a first remission must
have failed a full standard induction regimen
- Karnofsky performance status more than or equal to 50% for patients more than or
equal to 16 years and Lansky Performance Status (LPS) of more than or equal to 50%
for patients less than 16 years
- Organ function requirements: All patients must have adequate renal and liver
functions
Exclusion Criteria:
- Active acute or extensive chronic GvHD
- Immunosuppressive agents to prevent or treat GvHD within 2 weeks prior to
blinatumomab treatment
- Evidence for current CNS involvement by ALL (CNS 2, CNS 3) or testicular involvement
by ALL
- History of relevant CNS pathology or current relevant CNS pathology
- History of autoimmune disease with potential CNS involvement or current autoimmune
disease
- Any HSCT within 3 months prior to blinatumomab treatment
- Cancer chemotherapy within 2 weeks prior to blinatumomab treatment (except for
intrathecal chemotherapy and/or low dose maintenance therapy such as vinca alkaloids,
mercaptopurine, methotrexate, glucocorticoids)
- Chemotherapy related toxicities that haven't resolved to less than or equal to Grade
2
- Radiotherapy within 2 weeks prior to blinatumomab treatment
- Immunotherapy (e.g. rituximab, alemtuzumab) within 6 weeks prior to blinatumomab
treatment
- Any investigational product within 4 weeks prior to study entry
- Previous treatment with blinatumomab
- Active severe infection, any other concurrent disease or medical condition that could
be exacerbated by the treatment or would seriously complicate compliance with the
protocol
- Known infection with human immunodeficiency virus (HIV) or chronic infection with
hepatitis B virus (HbsAg positive) or hepatitis C virus (anti-HCV positive)